2015 Press Releases

Keyword Search
 
2017 | 2016 | 2015 | 2014 | 2013
DateTitle 
10/15/15Exicure Co-Founder Awarded Inaugural Sackler Prize
SKOKIE, Ill., Oct. 15, 2015 (GLOBE NEWSWIRE) -- Exicure is pleased to announce that Chad A. Mirkin, Ph.D., co-founder and director of Exicure, has been named the inaugural recipient of the Raymond and Beverly Sackler Prize in Convergence Research from the National Academy of Sciences. Dr. Mirkin is being awarded the prize for his advances in biomedicine, including spherical nucleic acid (SNA) technology. The prize was presented Tuesday, October 13, 2015, at the National Academy of Sciences build... 
Printer Friendly Version
04/22/15AuraSense Therapeutics Announces Publication of Preclinical Data Demonstrating Immuno-Modulation by its Proprietary Spherical Nucleic Acid Platform
SKOKIE, Ill., April 22, 2015 (GLOBE NEWSWIRE) -- AuraSense Therapeutics, the pioneer in developing Spherical Nucleic Acid (SNA™) constructs as gene regulatory and immunotherapeutic agents, today announced a new publication in Proceedings of the National Academy of Sciences of the United States of America [Radovic-Moreno et al, 2015. 112 (13) 3892–3897] demonstrating the immunomodulatory effects of SNA constructs in preclinical models of lymphoma and non-alcoholic steatohepatitis (NASH). In lymph... 
Printer Friendly Version
02/04/15AuraSense Therapeutics Adds to Series C Financing
SKOKIE, Ill., Feb. 4, 2015 (GLOBE NEWSWIRE) -- AuraSense Therapeutics, the pioneer in developing Spherical Nucleic Acid (SNA™) constructs as gene regulatory and immunotherapeutic agents, today announced a second closing of their Series C financing, now totaling over $18 million. The Chicago -based Company has attracted more than $27 million in capital. "We are gratified to continue to attract quality investors who share our dedication to creating precision medicines for a safer, more effective w... 
Printer Friendly Version

Print Page  | E-mail Page  | RSS Feeds  | E-mail Alerts  | IR Contacts  | Financial Tear Sheet